Circio announces that partner IOVaxis Therapeutics has exercised the option for an exclusive license to mutant RAS cancer vaccine TG01 in China
· The option exercise grants IOVaxis an exclusive license to develop and commercialize mutant RAS vaccines TG01/TG02 in Greater China and Singapore · IOVaxis will make an immediate down payment of USD 300.000 on the agreed option exercise fee of USD 3.000.000 · Circio has granted IOVaxis a six-month payment extension on the remainder of the option exercise fee · IOVaxis intends to initiate its first TG01 clinical trial in pancreatic cancer during 2024 Oslo, Norway 19 March 2024 – Circio Holding ASA (OSE: CRNA) announces that following approval of the investigational new drug (